Unveiling the association between HMG-CoA reductase inhibitors and bladder cancer: A comprehensive analysis using Mendelian randomization, animal models, and transcriptomics
Our study identifies HMG-CoA reductase (HMGCR) inhibitors, particularly simvastatin, as potential agents for reducing bladder cancer (BLCA) risk, and provides potential insight for clinical practice for BLCA treatment or adjuvant therapy.
